Form 8-K - Current report:
SEC Accession No. 0001104659-26-081797
Filing Date
2026-07-08
Accepted
2026-07-08 16:23:21
Documents
12
Period of Report
2026-07-06
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2620055d1_8k.htm   iXBRL 8-K 30371
2 EXHIBIT 16.1 tm2620055d1_ex16-1.htm EX-16.1 1922
  Complete submission text file 0001104659-26-081797.txt   199240

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oncy-20260706.xsd EX-101.SCH 3041
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oncy-20260706_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oncy-20260706_pre.xml EX-101.PRE 22376
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2620055d1_8k_htm.xml XML 3220
Mailing Address SUITE 325, 4350 EXECUTIVE DRIVE SAN DIEGO CA 92121
Business Address SUITE 325, 4350 EXECUTIVE DRIVE SAN DIEGO CA 92121 4036707377
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 980541667 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38512 | Film No.: 261162626
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)